Suppr超能文献

按种族比较密苏里州女性原位导管癌的治疗与结局。

Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.

作者信息

Madubata Chinwe C, Liu Ying, Goodman Melody S, Yun Shumei, Yu Jennifer, Lian Min, Colditz Graham A

机构信息

Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA.

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Breast Cancer Res Treat. 2016 Dec;160(3):563-572. doi: 10.1007/s10549-016-4030-6. Epub 2016 Oct 22.

Abstract

PURPOSE

To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS).

PATIENTS AND METHODS

The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 and identified in the Missouri Cancer Registry. Logistic regression models were used to estimate odds ratios (ORs) of treatment for race. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of ipsilateral breast tumor (IBT) and contralateral breast tumor (CBT) for race.

RESULTS

There was no significant difference between Black and White women in utilization of mastectomy (OR 1.16; 95 % CI 0.99-1.35) or endocrine therapy (OR 1.19; 95 % CI 0.94-1.51). Despite no significant difference in underutilization of radiation therapy (OR 1.14; 95 % CI 0.92-1.42), Black women had higher odds of radiation delay, defined as at least 8 weeks between surgery and radiation (OR 1.92; 95 % CI 1.55-2.37). Among 9138 patients, 184 had IBTs and 326 had CBTs. Black women had a higher risk of IBTs (HR 1.69; 95 % CI 1.15-2.50) and a comparable risk of CBTs (HR 1.19; 95 % CI 0.84-1.68), which were independent of pathological features and treatment.

CONCLUSION

Racial differences in DCIS treatment and outcomes exist in Missouri. This study could not completely explain the higher risk of IBTs in Black women. Future studies should identify differences in timely initiation and completion of treatment, which may contribute to the racial difference in IBTs after DCIS.

摘要

目的

探讨治疗(手术、放射治疗和内分泌治疗)是否导致导管原位癌(DCIS)预后的种族差异。

患者与方法

分析纳入了1996年至2011年间在密苏里州癌症登记处确诊为DCIS的8184名非西班牙裔白人女性和954名非西班牙裔黑人女性。采用逻辑回归模型估计种族治疗的比值比(OR)。我们使用Cox比例风险回归模型估计种族同侧乳腺肿瘤(IBT)和对侧乳腺肿瘤(CBT)的风险比(HR)。

结果

黑人女性与白人女性在乳房切除术(OR 1.16;95%CI 0.99 - 1.35)或内分泌治疗(OR 1.19;95%CI 0.94 - 1.51)的使用上无显著差异。尽管在放射治疗利用不足方面无显著差异(OR 1.14;95%CI 0.92 - 1.42),但黑人女性放射治疗延迟的几率更高,放射治疗延迟定义为手术与放射治疗之间至少间隔8周(OR 1.92;95%CI 1.55 - 2.37)。在9138名患者中,184人发生IBT,326人发生CBT。黑人女性发生IBT的风险更高(HR 1.69;95%CI 1.15 - 2.50),发生CBT的风险相当(HR 1.19;95%CI 0.84 - 1.68),且这些风险与病理特征和治疗无关。

结论

密苏里州DCIS治疗和预后存在种族差异。本研究无法完全解释黑人女性IBT风险较高的原因。未来的研究应确定治疗及时启动和完成方面的差异,这可能导致DCIS后黑人女性IBT的种族差异。

相似文献

1
Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.
Breast Cancer Res Treat. 2016 Dec;160(3):563-572. doi: 10.1007/s10549-016-4030-6. Epub 2016 Oct 22.
2
Racial disparities in risk of second breast tumors after ductal carcinoma in situ.
Breast Cancer Res Treat. 2014 Nov;148(1):163-73. doi: 10.1007/s10549-014-3151-z. Epub 2014 Sep 27.
3
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.
J Natl Compr Canc Netw. 2018 Apr;16(4):387-394. doi: 10.6004/jnccn.2018.7003.
5
Impacts of Neighborhood Characteristics on Treatment and Outcomes in Women with Ductal Carcinoma of the Breast.
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1298-1306. doi: 10.1158/1055-9965.EPI-17-1102. Epub 2018 Aug 14.
8
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
J Natl Cancer Inst. 2015 Sep 30;107(12):djv263. doi: 10.1093/jnci/djv263. Print 2015 Dec.

引用本文的文献

2
Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome.
Breast Cancer Res. 2024 Sep 2;26(1):127. doi: 10.1186/s13058-024-01885-8.
3
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.
Breast Cancer Res Treat. 2024 Dec;208(3):577-587. doi: 10.1007/s10549-024-07453-0. Epub 2024 Aug 16.
7
Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Cancer. 2019 Sep 15;125(18):3225-3233. doi: 10.1002/cncr.32200. Epub 2019 May 23.
8
Impacts of Neighborhood Characteristics on Treatment and Outcomes in Women with Ductal Carcinoma of the Breast.
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1298-1306. doi: 10.1158/1055-9965.EPI-17-1102. Epub 2018 Aug 14.

本文引用的文献

1
Tamoxifen Initiation After Ductal Carcinoma In Situ.
Oncologist. 2016 Feb;21(2):134-40. doi: 10.1634/theoncologist.2015-0310. Epub 2016 Jan 14.
3
Racial disparities in risk of second breast tumors after ductal carcinoma in situ.
Breast Cancer Res Treat. 2014 Nov;148(1):163-73. doi: 10.1007/s10549-014-3151-z. Epub 2014 Sep 27.
4
Breast cancer version 3.2014.
J Natl Compr Canc Netw. 2014 Apr;12(4):542-90. doi: 10.6004/jnccn.2014.0058.
5
6
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.
Breast Cancer Res Treat. 2013 Jun;139(2):453-60. doi: 10.1007/s10549-013-2539-5. Epub 2013 Apr 27.
7
Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.
Cancer. 2013 Jan 1;119(1):150-7. doi: 10.1002/cncr.27707. Epub 2012 Jun 26.
8
Multi-institutional experience of ductal carcinoma in situ in black vs white patients treated with breast-conserving surgery and whole breast radiation therapy.
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e279-83. doi: 10.1016/j.ijrobp.2012.03.068. Epub 2012 Jun 5.
9
Adjuvant hormonal therapy use among women with ductal carcinoma in situ.
J Womens Health (Larchmt). 2012 Jan;21(1):35-42. doi: 10.1089/jwh.2011.2773. Epub 2011 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验